Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape i…

Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of …

Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for ea…

Guest: John Berk, MD Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flag…

Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…

Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and re…

Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…

Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…

Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for ea…

Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection…

Host: Marianna Fontana, MD The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. Building on a successful phase 1 study demonstrating vutrisiran's safety and effectiveness in reducing serum TTR, HELIOS is pavin…

Host: Jeffrey V. Matous, MD Guest: Donna Catamero, NP Guest: Ajai Chari, MD GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important …

Host: Carl Regillo, MD Guest: Jennifer I. Lim, MD, FARVO What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neo…

Host: Omer Abdul Hamid, MD Guest: Nancy Kuntz, MD Guest: Migvis Monduy, MD There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they …

Host: Arshad M. Khanani, MD, MA Guest: Theodore Leng, MD, MS Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on c…

Host: Tauseef Ali, MD, FACG, AGAF Host: Sabina Ali, MD Host: Neil Nandi, MD, FACP Host: Tina Aswani-Omprakash, MPH A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.…

Host: Dmitry M. Yaranov, MD During the clinical course of heart failure, even with guideline directed medical therapy, many patients still experience symptoms that negatively impact their quality of life. Baroreflex activation therapy, or BAT, is an FDA approved therapy for patients with heart failure with reduced ejection fraction that has been sh…

Host: Deborah Siegal, MD, MSc, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help cli…

Host: Deborah Siegal, MD, MSc, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help cli…

Host: Scott Kaatz, DO, MSc, FACP, SFHM Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help c…

Host: Scott Kaatz, DO, MSc, FACP, SFHM Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help c…

Host: Bruce L. Davidson, MD, MPH Host: Victor F. Tapson, MD Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of t…

Host: Victor F. Tapson, MD Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians ef…

Host: Bruce L. Davidson, MD, MPH Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinici…

Host: Bruce L. Davidson, MD, MPH Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinici…

Host: Alfonso J. Tafur, MD, MS, MBA, RPVI Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the compon…

Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels…

Host: Alfonso J. Tafur, MD, MS, MBA, RPVI Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to hel…

Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels…

Host: Anne Marie Morse, DO, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be …

Host: Seema Khosla, MD, FCCP, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can b…

Host: Michael E. Yurcheshen, MD, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and ca…

Host: Kevin Trice, MD One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily imple…

Host: Alcibiades J. Rodriguez, MD, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and …

Host: Meghan Mooradian, MD This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB t…

Guest: Durga Borkar, MD, MMCi Guest: Diana Do, MD Guest: Peter K. Kaiser, MD The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include rece…

Host: Arun B. Jesudian, MD Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorient…

Host: Robert Rahimi, MD, MSCR Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorient…

Host: Patricia P. Bloom, MD Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorien…

Host: Patricia P. Bloom, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, an…

Host: Patricia P. Bloom, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, an…

Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, …

Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and…

Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, and…

Host: Michael A. Levine, MD, FAAP, MACE, FACP Host: B. Michelle Schweiger, DO, MPH Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defi…

Host: Michael A. Levine, MD, FAAP, MACE, FACP Host: B. Michelle Schweiger, DO, MPH Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defi…

Host: Michael A. Levine, MD, FAAP, MACE, FACP Host: B. Michelle Schweiger, DO, MPH Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defi…

Host: Michael A. Levine, MD, FAAP, MACE, FACP Host: B. Michelle Schweiger, DO, MPH Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defi…

Guest: David Johnson, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to …

Guest: Douglas Rex, MD Guest: David Johnson, MD In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educatio…